Latest News - Phase 3/4 Trials

Friday, January 27, 2017 | Personnel/Company News, Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, Novan

Topline Results from Novan's SB204 Phase 3 Pivotal Trials: Inconsistent Across Trials

Novan, Inc. (NASDAQ:NOVN) today announced  top-line results from the Company’s two, replicate Phase 3 pivotal clinical trials for SB204 in the treatment of acne vulgaris. In the intent-to-t…

Read the full story

Monday, November 28, 2016 | Personnel/Company News, Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101

Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, acco…

Read the full story

Wednesday, October 19, 2016 | Personnel/Company News, Phase 3/4 Trials

Study Calls Attention to Negative Impact, Need for Treatment of SK

Patients with asymptomatic seborrheic keratosis (SK) are bothered by highly visible skin lesions and are very interested in treatment to improve their appearance, even if a cost were associated with t…

Read the full story

Monday, October 10, 2016 | Phase 3/4 Trials, PracticalDermatology.com

Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patients

Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence…

Read the full story

Monday, October 10, 2016 | Phase 3/4 Trials, PracticalDermatology.com

Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neck

Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or…

Read the full story

Monday, October 03, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, National Eczema Association , Regeneron, Sanofi

Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studies

Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in t…

Read the full story

Monday, August 15, 2016 | Phase 3/4 Trials

Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infections

The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline …

Read the full story

Wednesday, July 27, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Psoriasis

Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europe

Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currentl…

Read the full story

Friday, July 15, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Product Launches and Updates

Revance’s Injectable Toxin to Enter Phase 3 Trials

It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second h…

Read the full story

Wednesday, June 08, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

New Psoriasis Drug Taltz Shows Benefit Through 60 Weeks

Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings app…

Read the full story

Monday, June 06, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Regeneron, Sanofi

Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Study

Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD …

Read the full story

Thursday, June 02, 2016 | Phase 3/4 Trials, Product Launches and Updates

Dermira’s DRM04 Shows Promise for Primary Axillary Hyperhidrosis

Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit …

Read the full story

Thursday, April 21, 2016 | Acquisitions and Mergers, Phase 3/4 Trials, PracticalDermatology.com, Allergan

Allergan Acquires Topokine Therapeutics

Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, All…

Read the full story

Thursday, April 07, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, Alphaeon

Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trials

Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two …

Read the full story

Friday, February 26, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Galderma

Galderma to Begin Two Phase III Restylane Trials

Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when administered via cannula for per…

Read the full story
Load More